OPKO Adds to Growing Technology Portfolio Through Strategic Investment in Biotechnology Company Engaged in the Development of a

  OPKO Adds to Growing Technology Portfolio Through Strategic Investment in
  Biotechnology Company Engaged in the Development of a New Generation of

Business Wire

MIAMI -- October 10, 2013

OPKO Health, Inc. (NYSE: OPK) has agreed to make an investment in Zebra
Biologics, Inc. (“Zebra”), a privately held biotechnology company focused on
the discovery and development of biosuperior antibody therapeutics and complex
drug targets. Zebra’s patented platform is an advanced version of a core
technology that underlies the discovery and commercial success of AbbVie
Inc.’s Humira™, developed by Richard Lerner, M.D., at The Scripps Research
Institute. The technology allows for the selection of antibodies for function
rather than through simple binding. Zebra has already developed an early
pre-clinical pipeline of candidate antibodies with significant commercial
potential in regulating diabetes and obesity, cancer, and treatment of
neurological disease.

In addition to Phillip Frost, M.D., OPKO’s Chairman and Chief Executive
Officer, Zebra’s directors and founders also include Dr. Lerner; Dr. Ronald M.
Lindsay, a director and Executive Vice President for Strategic Planning of
Sequenom, Inc. (NASDAQ: SQNM), a company providing innovative diagnostic
testing and genetic analysis solutions; Mr.  Gao Feng, chairman and president
of Beijing based Hongye International Investment Group, which operates in the
energy, natural resources, finance and bio-pharmaceuticals industries; and Dr.
Paul Greengard, Vincent Astor Professor at Rockefeller University and
recipient of a 2000 Nobel Prize for his work concerning signal transduction in
the nervous system.

“This participation is in keeping with a core strategy of investing in other
companies that have valuable proprietary technology and significant future
potential for OPKO,” said Dr. Frost. “We are hopeful that our portfolio of
investments will continue to appreciate in value as the companies and
technologies mature. In some cases, our investments offer opportunities for
OPKO to obtain new products; as well as the possibility to monetize them at an
appropriate time.”


OPKO is a multinational biopharmaceutical and diagnostics company that seeks
to establish industry leading positions in large, rapidly growing markets by
leveraging its discovery, development and commercialization expertise and
novel and proprietary technologies. For more information, visit


This press release includes forward looking statements, within the meaning of
the Private Securities Litigation Reform Act of 1995, which are subject to
risks and uncertainties that could cause actual results to differ materially
from those anticipated. Such statements may relate to OPKO's plans, objectives
and expected financial and operating results, including statements regarding
the commercial potential of Zebra’s early pre-clinical pipeline of candidate
antibodies, expected benefits from OPKO’s investment in Zebra and other
companies with valuable proprietary technology, the value of OPKO’s portfolio
of investments and whether the investments will continue to appreciate in
value, whether the investments offer opportunities for new products, and
whether OPKO will be able to monetize the investments at the appropriate time.
The words "may," "could," "would," "will," "believe," "anticipate,"
"estimate," "expect," "intend," "plan," and similar expressions or variations
thereof are intended to identify forward-looking statements. Investors are
cautioned that any such forward-looking statements are not guarantees of
future performance and involve risks and uncertainties, many of which are
beyond OPKO's ability to control. The risks and uncertainties that may affect
forward looking statements include those described in OPKO’s filings with the
Securities and Exchange Commission, as well as risks inherent in funding,
developing and obtaining regulatory approvals of new, commercially-viable and
competitive products and treatments, general market factors, competitive
product development, product availability, federal and state regulations and
legislation, the regulatory process for new products and indications,
manufacturing issues that may arise, patent positions and litigation, among
other factors For more details about the risks and uncertainties related to
OPKO's business, refer to OPKO's filings with the Securities and Exchange
Commission. OPKO undertakes no obligation to publicly update or revise any
forward looking statements, whether as a result of new information, future
events or otherwise.


OPKO Health, Inc.
Steve D. Rubin, 305-575-4100
Executive Vice President — Administration
Juan F. Rodriguez, 305-575-4100
Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.